4.3 Article

Zinc Intake From Supplements and Diet and Prostate Cancer

期刊

出版社

ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/01635580802419749

关键词

-

资金

  1. National Cancer Institute [R01 CA74846, R25 CA94880]
  2. NATIONAL CANCER INSTITUTE [R01CA074846, R25CA094880] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Laboratory and animal studies suggest a beneficial effect of zinc on prostate cancer. We evaluated the association between dietary and supplemental zinc and prostate cancer within the VITamins And Lifestyle (VITAL) cohort, a study specifically designed to evaluate the impact of dietary supplements and cancer risk. Of 35,242 men who completed the baseline dietary and supplemental questionnaire, 832 men developed invasive prostate cancers between October 2000 and December 2004. Ten-year average intake of supplemental zinc was not associated with a reduced prostate cancer risk overall (adjusted hazard ratio (HR) = 0.82 (95% confidence interval (CI) 0.58-1.14) for 15mg/day vs. nonuse, P for trend = 0.44); however, risk of advanced prostate cancer (regionally invasive or distant metastatic, n = 123) decreased with greater intake of supplemental zinc (adjusted HR = 0.34, 95% CI = 0.13-1.09 for 10-yr average intake 15 mg/day vs. nonuse, P for trend = 0.04). Dietary zinc was not associated with prostate cancer. In this prospective cohort, long-term supplemental zinc intake was associated with reduced risk of clinically relevant advanced disease. This study had limited ability to study early-stage disease because detection of early-stage disease is highly related to having a PSA test, and information on PSA was only available at baseline. Because few other epidemiologic studies have investigated the association between zinc and prostate cancer, and these have not yielded consistent findings, further research is needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据